ReviewExpert review of neurotherapeutics2018
Therapies for mobility disability in persons with multiple sclerosis.
Review in Expert review of neurotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy.CNS drugs · 2025Pooled it
- Effectiveness of transcranial direct current stimulation on balance and gait in patients with multiple sclerosis: systematic review and meta-analysis of randomized clinical trials.Journal of neuroengineering and rehabilitation · 2023Pooled it
- Effect of web-implemented exercise interventions on depression and anxiety in patients with neurological disorders: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Repetitive transcranial magnetic stimulation for treatment of limb spasticity following multiple sclerosis: a systematic review and meta-analysis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Pooled it
- Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.European journal of neurology · 2026Trial
- Effects of a 6-Week Treadmill Training With and Without Virtual Reality on Frailty in People With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2025Trial
- The Effectiveness of Guided Imagery on Walking and Balance Dysfunction in Patients With Multiple Sclerosis: A Randomized Controlled Trial.Behavioural neurology · 2025Trial
- Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis.BMC neurology · 2024Trial
- Trial
- I Can Step Clearly Now, the TENS Is On: Transcutaneous Electric Nerve Stimulation Decreases Sensorimotor Uncertainty during Stepping Movements.Sensors (Basel, Switzerland) · 2022Trial
- Peripheral Nerve Injury and Denervation-Induced Sarcopenia with a Focus on Pharmacological Dual-Target Strategies.Biomolecules & therapeutics · 2026Review
- Learning Beyond the Clinic: Can Point of Choice Visual Feedback Prompts Elicit Motor Behavior Changes in Persons with Multiple Sclerosis?Research square · 2026Article
- A systematic review of economic evaluations of community-based healthcare interventions for neurodisability management.Health economics review · 2026Review
- A narrative review of clinical practice guidelines for the application of physical therapy and rehabilitation procedures in the management of multiple sclerosis.Neurosciences (Riyadh, Saudi Arabia) · 2025Review
- Functional Mobility Assessment in People with Multiple Sclerosis.Neurology international · 2025Article
- Body Composition and Its Outcomes and Management in Multiple Sclerosis: Narrative Review.Nutrients · 2025Review
- Restore axonal conductance in a locally demyelinated axon with electromagnetic stimulation.Journal of neural engineering · 2025Article
- Subjective Successful Aging in the Presence of Mobility Disability.The Gerontologist · 2024Article
- The therapeutic potential of exercise for improving mobility in multiple sclerosis.Frontiers in physiology · 2024Review
- Developing a community-engaged wheelchair exercise program for persons with MS: community advisory board formation and feedback.Disability and rehabilitation. Assistive technology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionMobility disability is one of the most widespread and impactful consequences of multiple sclerosis (MS). Disease modifying drugs (DMDs) may delay the progression of disability over time; however, there is minimal evidence supporting the efficacy of DMDs for reversing mobility disability or restoring ambulatory function in persons with MS. Areas covered: This review outlines symptomatic pharmacologic and non-pharmacologic therapeutic approaches that target mobility disability with the goal of restoring and improving walking function. First, the efficacy of dalfampridine, currently the only Food and Drug Administration approved symptomatic pharmacologic agent that improves walking in persons with MS is described. Next, a review of the efficacy of non-pharmacologic therapies for improving walking, including exercise training, physical therapy, and gait training is given. Last, guidance on future research on mobility in MS is provided by emphasizing the importance of combinatory treatment approaches that include multiple intervention modalities, as the best treatment plan likely involves a comprehensive, multidisciplinary approach. Expert commentary: There has been an increased effort to develop symptom-specific treatments in MS that directly target mobility disability; however, more research is needed to determine the efficacy of these rehabilitative strategies alone and together for improving walking in persons with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.